Table 2 HES dose administered and major findings of included randomized trials
Trial | Days on HES | Mean mL·kg-1 HES | Major Findings | |
|---|---|---|---|---|
| Â | Â | Daily | Cumulative | Â |
Falk et al., 1988 [9] | 1 | 70.5†| 70.5†| In HES 450/0.7 group PTT increased by 20 s (p = 0.01) and platelet count decreased by 158 × 103 mm-3 (p = 0.01); no significant PTT or platelet count change in albumin group |
Rackow et al., 1989 [7] | 1 | 12.9†| 12.9†| FVIII:c declined 45% in the HES 200/0.5 group compared with 5% in the albumin group (p = 0.05) |
Boldt et al., 1995 [17,18] | 5 | 8.5 | 42.3 | Plasma thrombomodulin increased in the albumin group and remained unchanged in the HES 200/0.5 group (p < 0.05); plasma protein C among HES 200/0.5 recipients increased on days 4 and 5 without corresponding change in the albumin group (p < 0.05); maximum platelet aggregation declined in both groups (p < 0.05) |
Boldt et al., 1996 [19] | 5 | 11.0 | 55.2 | HES 200/0.5 but not albumin increased cardiac index, RVEF, Pao2/Fio2, Do2I and Vo2I and decreased SVRI (p < 0.05 for all comparisons); pHi decreased in albumin but not HES 200/0.5 group (p < 0.05) |
Boldt et al., 1996 [20] | 5 | 12.7 | 63.7 | Circulating sELAM-1 and sICAM-1 concentrations reduced by HES 200/0.5 compared with albumin (p < 0.05 for both comparisons) |
Boldt et al., 1996 [21] | 5 | 11.0 | 49.8 | Vasopressin, endothelin-1 and norepinephrine decreased and pHi increased in HES 200/0.5 but not albumin group (p < 0.05 for all comparisons); ANP increased by albumin but not HES 200/0.5 (p < 0.05) |
Boldt et al., 1998 [22] | 5 | 12.5 | 62.4 | Pao2/Fio2, Do2I and Vo2I increased and lactate decreased by HES 200/0.5 but not albumin (p < 0.05 for all comparisons); no differences in incidence of renal failure, platelet count, PT or aPTT |
Asfar et al., 2000 [23] | 1 | 7.9 | 7.9 | Gelatin but not HES 200/0.62 increased pHi (p < 0.001) and decreased CO2 gastric mucosal arterial gradient (p < 0.0005) |
Schortgen et al., 2001 [24] | 4‡ | 14.0‡ | 31.0‡ | HES 200/0.62 exposure an independent risk factor for ARF (adjusted odds ratio, 2.57; CI 1.13–5.83) |
Molnár et al., 2004 [25] | 1 | 14.3†| 14.3†| No differences detected in ITBVI, EVLW or Pao2/Fio2 |
Palumbo et al., 2006 [26] | 5 | --§ | --§ | Target PCWP of 15–18 mm Hg maintained by both colloids; temperature, MAP, PAP, CVP, heart rate and urine output remained stable without differences between groups; HES 130/0.4, but not albumin, increased cardiac index and several oxygenation parameters (Pao2/Fio2, Do2I and Vo2I) and decreased APACHE II score (p < 0.05 for all within-group comparisons) |
Brunkhorst et al., 2008 [27] | 21 | --§ | 70.4¶ | Greater ARF incidence in HES 200/0.5 group (odds ratio, 1.81; CI, 1.22–2.71; p = 0.002); increased mortality at higher HES 200/0.5 doses (odds ratio, 3.08; CI, 1.78–5.37; p < 0.001) |